

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently Amended) An isolated monoclonal antibody or antigen-binding-fragment thereof that binds to the extracellular domain of the human KIM-1 polypeptide of SEQ ID NO:7 at an epitope within or overlapping the amino acid sequence: SSDGLWNNNQTLFLEHS (SEQ ID NO:1).

2. (Previously Presented) An isolated antibody or antigen-binding-fragment thereof that has the same epitope specificity as the antibody produced by the hybridoma deposited in the ATCC under Accession No. PTA-3350.

3. (Previously Presented) An isolated antibody or antigen-binding-fragment thereof that crossblocks binding of the antibody produced by the hybridoma deposited in the ATCC under Accession No. PTA-3350.

4. (Currently Amended) The isolated antibody or antigen-binding fragment thereof of claim 1, wherein the monoclonal antibody is a humanized antibody.

5. (Currently Amended) The isolated antibody or antigen-binding-fragment thereof of claim 1, wherein the monoclonal antibody is a fully human antibody.

6. (Previously Presented) A conjugate comprising the isolated antibody or antigen-binding fragment thereof of claim 1, 2 or 3 linked to a detectable label.

7. (Previously Presented) A conjugate or fusion polypeptide comprising the isolated antibody or antigen-binding fragment thereof of claim 1, 2 or 3 and a toxin moiety.

8. (Original) An antibody produced by the hybridoma deposited with ATCC under Accession No. PTA-3350.

9. (Original) Hybridoma ABE3, deposited with ATCC under Accession No. PTA-3350.

10. (Cancelled)

11. (Previously Presented) A composition comprising the isolated antibody or antigen-binding fragment thereof of claim 1, 2 or 3 and a pharmaceutically acceptable carrier.

12-22. (Cancelled)

23. (Currently Amended) An ~~The~~ isolated antibody or antigen-binding fragment thereof that binds to the extracellular domain of the human KIM-1 polypeptide of SEQ ID NO:7 at of ~~claim 1, wherein the antibody or antigen-binding fragment thereof binds to~~ an epitope within the amino acid sequence: SSDGLWNNNQTLFLEHS (SEQ ID NO:1).

24. (Previously Presented) The isolated antibody or antigen-binding fragment thereof of claim 2, wherein the antibody is a humanized antibody.

25. (Previously Presented) The isolated antibody or antigen-binding fragment thereof of claim 3, wherein the antibody is a humanized antibody.

26. (Previously Presented) The isolated antibody or antigen-binding fragment thereof of claim 23, wherein the antibody is a humanized antibody.

27. (Previously Presented) The isolated antibody or antigen-binding fragment thereof of claim 2, wherein the antibody is a fully human antibody.

28. (Previously Presented) The isolated antibody or antigen-binding fragment thereof of claim 3, wherein the antibody is a fully human antibody.

29. (Previously Presented) The isolated antibody or antigen-binding fragment thereof of claim 23, wherein the antibody is a fully human antibody.

30. (Cancelled)

31. (Previously Presented) The isolated antibody or antigen-binding fragment thereof of claim 2, wherein the antibody is a monoclonal antibody.

32. (Previously Presented) The isolated antibody or antigen-binding fragment thereof of claim 3, wherein the antibody is a monoclonal antibody.

33. (Previously Presented) The isolated antibody or antigen-binding fragment thereof of claim 23, wherein the antibody is a monoclonal antibody.

34. (Currently Amended) The isolated antibody or antigen-binding fragment thereof of claim 1, wherein the monoclonal antibody is a single chain antibody.

35. (Previously Presented) The isolated antibody or antigen-binding fragment thereof of claim 2, wherein the antibody is a single chain antibody.

36. (Previously Presented) The isolated antibody or antigen-binding fragment thereof of claim 3, wherein the antibody is a single chain antibody.

37. (Previously Presented) The isolated antibody or antigen-binding fragment thereof of claim 23, wherein the antibody is a single chain antibody.

38. (Currently Amended) The isolated antibody or antigen-binding fragment thereof of claim 1, wherein the monoclonal antibody or antigen-binding fragment thereof is ~~a polyclonal antibody~~, a chimeric antibody, an F_{ab} fragment, an $F_{(ab)2}$ fragment, an $F_{ab'}$ fragment, an F_{sc} fragment, or an F_v fragment.

39. (Previously Presented) The isolated antibody or antigen-binding fragment thereof of claim 2, wherein the antibody or antigen-binding fragment thereof is a polyclonal antibody, a chimeric antibody, an F_{ab} fragment, an $F_{(ab)2}$ fragment, an $F_{ab'}$ fragment, an F_{sc} fragment, or an F_v fragment.

40. (Previously Presented) The isolated antibody or antigen-binding fragment thereof of claim 3, wherein the antibody or antigen-binding fragment thereof is a polyclonal antibody, a chimeric antibody, an F_{ab} fragment, an $F_{(ab)2}$ fragment, an $F_{ab'}$ fragment, an F_{sc} fragment, or an F_v fragment.

41. (Previously Presented) The isolated antibody or antigen-binding fragment thereof of claim 23, wherein the antibody or antigen-binding fragment thereof is a polyclonal antibody, a chimeric antibody, an F_{ab} fragment, an $F_{(ab)2}$ fragment, an $F_{ab'}$ fragment, an F_{sc} fragment, or an F_v fragment.

42. (New) An isolated antibody or antigen-binding-fragment thereof that binds to the extracellular domain of the human KIM-1 polypeptide of SEQ ID NO:7, when expressed on the surface of a cell, at an epitope within or overlapping the amino acid sequence: SSDGLWNNNQTLFLEHS (SEQ ID NO:1).

43. (New) The isolated antibody or antigen-binding fragment thereof of claim 42, wherein the antibody is a humanized antibody.

44. (New) The isolated antibody or antigen-binding fragment thereof of claim 42, wherein the antibody is a fully human antibody.

45. (New) The isolated antibody or antigen-binding fragment thereof of claim 42, wherein the antibody is a monoclonal antibody.

46. (New) The isolated antibody or antigen-binding fragment thereof of claim 42, wherein the antibody is a single chain antibody.

47. (New) The isolated antibody or antigen-binding fragment thereof of claim 42, wherein the antibody or antigen-binding fragment thereof is a polyclonal antibody, a chimeric antibody, an F_{ab} fragment, an $F_{(ab')_2}$ fragment, an $F_{ab'}$ fragment, an F_{sc} fragment, or an F_v fragment.

48. (New) The isolated antibody or antigen-binding fragment thereof of claim 42, wherein the antibody or antigen-binding fragment thereof binds to an epitope within the amino acid sequence: SSDGLWNNNQTLFLEHS (SEQ ID NO:1).

49. (New) The isolated antibody or antigen-binding fragment thereof of claim 42, wherein the antibody is a humanized antibody.

50. (New) The isolated antibody or antigen-binding fragment thereof of claim 48, wherein the antibody is a fully human antibody.

51. (New) The isolated antibody or antigen-binding fragment thereof of claim 48, wherein the antibody is a monoclonal antibody.

52. (New) The isolated antibody or antigen-binding fragment thereof of claim 48, wherein the antibody is a single chain antibody.

53. (New) The isolated antibody or antigen-binding fragment thereof of claim 48, wherein the antibody or antigen-binding fragment thereof is a polyclonal antibody, a chimeric antibody, an F_{ab} fragment, an $F_{(ab')_2}$ fragment, an $F_{ab'}$ fragment, an F_{sc} fragment, or an F_v fragment.